ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences

ProQR Therapeutics announced upcoming presentations of its Axiomer RNA editing platform at major conferences including TIDES Europe, AASLD The Liver Meeting 2026, and Nature Conferences RNA at the Bench and Bedside V. The company will showcase clinical data from its Phase 1 AX-0810 study demonstrating favorable safety and target engagement, as well as preclinical data for next-generation candidate AX-0811, with initial Phase 1 data expected in early January 2027.